Japan Tissue Engineering Co., Ltd. (J-TEC) | Creating a Future for Regenerative Medicine

Aug. 8, 2022News Release

Supporting the Early Commercialization of Regenerative Medicine for Corneal Endothelium

— Partial Product Development Contract with ActualEyes Inc. —
Aug. 5, 2022News Release

Toward creation of a database for results of skin irritation tests using an alternative to animal testing

– With a grant from JSAAE, 6 corporations continue contributing jointly to the cosmetics industry –
Jul. 27, 2022Columns / Topics

"Innovators Under 35 Japan"

J-TEC's president & CEO Ken-ichiro Hata became a judge
Jul. 20, 2022Columns / Topics

What was gained through the re-examination of JACC
Jul. 5, 2022News Release

Re-examination of Autologous Cultured Cartilage “JACC”

Columns & Topics

Jul. 27, 2022[PICK UP]

"Innovators Under 35 Japan"

Jul. 20, 2022[INSIDE REGENERATIVE MEDICINE]

What was gained through the re-examination of JACC

Jul. 4, 2022[PICK UP]

Tales of Regenerative Medicine Vol.8

Jun. 1, 2022[INSIDE REGENERATIVE MEDICINE]

Society, medicine, regenerative medicine, and our corporate sustainability

May. 18, 2022[PICK UP]

Tales of Regenerative Medicine Vol.7

Apr. 20, 2022[PICK UP]

Tales of Regenerative Medicine Vol.6

For
Patients and their Families

Regenerative Medicine
Developers

Cultured Human
Tissue Users